9416 Federal Register / Vol. 75, No. 40 / Tuesday, March 2, 2010 / Notices 

Karen V. Gregory, 

Secretary. 

[FR Doc. 2010–4202 Filed 3–1–10; 8:45 am] 

BILLING CODE 6730–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Advisory Committee Information 

Hotline 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that we have revised the Advisory 

Committee Information Hotline (the 

hotline). The hotline provides the 

public with access to the most current 

information available on FDA advisory 

committee meetings. This notice 

supersedes all previously published 

announcements of FDA’s Advisory 

Committee Information Hotline. 

FOR FURTHER INFORMATION CONTACT: 

Michael F. Ortwerth, Director, Advisory 

Committee Oversight and Management 

Staff (HF–4), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–827–1220. 

SUPPLEMENTARY INFORMATION: The 

Advisory Committee Information 

Hotline can be accessed by dialing 1– 

800–741–8138 or 301–443–0572. The 

advisory committee meeting 

information and information updates 

can also be accessed via FDA’s Advisory 

Committee Internet site at http:// 

www.fda.gov/AdvisoryCommittees/ 

default.htm. 

Each advisory committee is assigned 

a 10-digit number. This 10-digit number 

will appear in each individual notice of 

meeting. The public can obtain 

information about a particular advisory 

committee meeting by using the 

committee’s 10-digit number. 

Information on the hotline is 

preliminary and may change before a 

meeting is actually held. The hotline 

will be updated when such changes are 

made. The following is a list of each 

advisory committee’s 10-digit number to 

be used when accessing the hotline. The 

list has been updated to add the newly 

established advisory committee in the 

Center for Tobacco called the Tobacco 

Products Scientific Advisory 

Committee. 

Advisory Committee 10-Digit Access Number 

OFFICE OF THE COMMISSIONER 

Pediatric Advisory Committee 8732310001 

Risk Communication Advisory Committee 8732112560 

Science Board to the FDA 3014512603 

CENTER FOR BIOLOGICS EVALUATION AND RESEARCH 

Allergenic Products Advisory Committee 3014512388 

Blood Products Advisory Committee 3014519516 

Cellular, Tissue & Gene Therapies Advisory Committee 3014512389 

Transmissible Spongiform Encephalopathies Advisory Committee 3014512392 

Vaccines and Related Biological Products Advisory Committee 3014512391 

CENTER FOR DRUG EVALUATION AND RESEARCH 

Anesthetic and Life Support Drugs Advisory Committee 3014512529 

Anti-Infective Drugs Advisory Committee 3014512530 

Antiviral Drugs Advisory Committee 3014512531 

Arthritis Advisory Committee 3014512532 

Cardiovascular and Renal Drugs Advisory Committee 3014512533 

Dermatologic and Ophthalmic Drugs Advisory Committee 3014512534 

Drug Safety and Risk Management Advisory Committee 3014512535 

Endocrinologic and Metabolic Drugs Advisory Committee 3014512536 

Gastrointestinal Drugs Advisory Committee 3014512538 

Nonprescription Drugs Advisory Committee 3014512541 

Oncologic Drugs Advisory Committee 3014512542 

Peripheral and Central Nervous System Drugs Advisory Committee 3014512543 

Pharmaceutical Science & Clinical Pharmacology, Advisory Committee for (formerly 

Advisory Committee for Pharmaceutical Science) 

3014512539 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES

Federal Register / Vol. 75, No. 40 / Tuesday, March 2, 2010 / Notices 9417 

Advisory Committee 10-Digit Access Number 

Psychopharmacologic Drugs Advisory Committee 3014512544 

Pulmonary-Allergy Drugs Advisory Committee 3014512545 

Reproductive Health Drugs, Advisory Committee for 3014512537 

CENTER FOR FOOD SAFETY AND APPLIED NUTRITION 

Food Advisory Committee 3014510564 

CENTER FOR DEVICES AND RADIOLOGICAL HEALTH 

Device Good Manufacturing Practice Advisory Committee 3014512398 

Medical Devices Advisory Committee comprised of 18 panels) 

Anesthesiology and Respiratory Therapy Devices Panel 3014512624 

Circulatory System Devices Panel 3014512625 

Clinical Chemistry and Clinical Toxicology Devices Panel 3014512514 

Dental Products Panel 3014512518 

Ear, Nose, and Throat Devices Panel 3014512522 

Gastroenterology-Urology Devices Panel 3014512523 

General and Plastic Surgery Devices Panel 3014512519 

General Hospital and Personal Use Devices Panel 3014512520 

Hematology and Pathology Devices Panel 3014512515 

Immunology Devices Panel 3014512516 

Medical Devices Dispute Resolution Panel 3014510232 

Microbiology Devices Panel 3014512517 

Molecular and Clinical Genetics Panel 3014510231 

Neurological Devices Panel 3014512513 

Obstetrics-Gynecology Devices 3014512524 

Ophthalmic Devices Panel 3014512396 

Orthopaedic and Rehabilitation Devices Panel 3014512521 

Radiological Devices Panel 3014512526 

National Mammography Quality Assurance Advisory Committee 3014512397 

Technical Electronic Product Radiation Safety Standards Committee 3014512399 

CENTER FOR TOBACCO 

Tobacco Products Scientific Advisory Committee 8732110002 

CENTER FOR VETERINARY MEDICINE 

Veterinary Medicine Advisory Committee 3014512548 

NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH (NCTR) 

Science Advisory Board to NCTR 3014512559 

The hotline will provide the most 

recent information available on 

upcoming advisory committee meetings, 

guidance for making an oral 

presentation during the open public 

hearing portion of a meeting, and 

procedures on obtaining copies of 

transcripts of advisory committee 

meetings. Because the hotline will 

communicate the most current 

information available about any 

particular advisory committee meeting, 

this system will provide interested 

parties with timely and equal access to 

such information. The hotline should 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES

9418 Federal Register / Vol. 75, No. 40 / Tuesday, March 2, 2010 / Notices 

also conserve agency resources by 

reducing the current volume of inquiries 

individual FDA offices and employees 

must handle concerning advisory 

committee schedules and procedures. 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app. 2) and 21 CFR part 14, 

relating to advisory committees. 

Dated: February 24, 2010. 

Joanne Less, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–4258 Filed 3–1–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 

Comment Request; Reinstatement of 

OMB No. 0925–0601/exp. 02/28/2010, 

Request for Human Embryonic Stem 

Cell Line To Be Approved for Use in 

NIH Funded Research 

SUMMARY: Under the provisions of 

Section 3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Institutes of Health (NIH) has submitted 

to the Office of Management and Budget 

(OMB) a reinstatement of approval of 

the information collection listed below. 

This proposed information collection 

was previously published in the Federal 

Register on September 25, 2009, page 

48973 and allowed 60 days for public 

comment. No public comments were 

received. The purpose of this notice is 

to allow an additional 30 days for public 

comment. The National Institutes of 

Health may not conduct or sponsor, and 

the respondent is not required to 

respond to, an information collection 

unless it displays a currently valid OMB 

control number. 

Proposed Collection: Title: Request for 

Human Embryonic Stem Cell Line to be 

Approved for Use in NIH Funded 

Research. Type of Information 

Collection Request: Revision, OMB 

0925–0601, Expiration Date 02/28/2010, 

Form Number: NIH 2890. Need and Use 

of Information Collection: The form is 

used by applicants to request that 

human embryonic stem cell lines be 

approved for use in NIH funded 

research. Frequency of response: 

Applicants may submit applications at 

any time; this request is a one-time 

submission. Affected Public: Business or 

other for-profit; Not-for-profit 

institutions; Federal Government; and 

State, Local or Tribal Government. Type 

of Respondents: Adult scientific 

professionals. The annual reporting 

burden is as follows: Estimated Number 

of Respondents: 160,135; Estimated 

Number of Responses per Respondent: 

1; Average Burden Hours per Response: 

14; and Estimated Total Annual Burden 

Hours Requested: 2,251,500. The 

estimated annualized cost to 

respondents is $78,802,500. 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the function of the 

agency, including whether the 

information will have practical utility; 

(2) The accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) Ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

Ways to minimize the burden of the 

collection of information on those who 

are to respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, should be directed to the: Office 

of Management and Budget, Office of 

Regulatory Affairs, 

OIRA_submission@omb.eop.gov or by 

fax to 202–395–6974, Attention: Desk 

Officer for NIH. To request more 

information on the proposed project or 

to obtain a copy of the data collection 

plans and instruments, contact: Ms. 

Mikia Currie, Division of Grants Policy, 

Office of Policy for Extramural Research 

Administration, NIH, Rockledge 1 

Building, Room 3505, 6705 Rockledge 

Drive, Bethesda, MD 20892–7974, or 

call non-toll-free number (301) 435– 

0941, or E-mail your request, including 

your address to: curriem@od.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30-days of the date of 

this publication. 

Dated: February 25, 2010. 

Mikia Currie, 

Office of Policy for Extramural Research 

Administration, OD, NIH. 

[FR Doc. 2010–4301 Filed 3–1–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Submission for OMB Review; 

Comment Request 

Title: Evaluation of Adolescent 

Pregnancy Prevention Approaches— 

Baseline Data Collection. 

OMB No.: ICRAS: 0970–0360. 

Description: The Administration for 

Children and Families (ACF), U.S. 

Department of Health and Human 

Services (HHS), is proposing a data 

collection activity as part of the 

Evaluation of Adolescent Pregnancy 

Prevention Approaches (PPA). PPA is 

being undertaken to expand available 

evidence on effective ways to reduce 

teen pregnancy. The evaluation will 

document and test a range of pregnancy 

prevention approaches in up to eight 

program sites. Program impacts will be 

estimated using a random assignment 

design, involving random assignment at 

the school, individual, or other level, 

depending on the program setting. The 

findings of the evaluation will be of 

interest to the general public, to policymakers, and to organizations interested 

in teen pregnancy prevention. 

This proposed information collection 

activity focuses on collecting baseline 

data from a self-administered 

questionnaire which will be used to 

perform meaningful analysis to 

determine significant program effects. 

Through a survey instrument, 

respondents will be asked to answer 

carefully selected questions about 

demographics and risk and protective 

factors related to teen pregnancy. As 

appropriate to each program being 

evaluated, youth records, performance, 

and program participation data will also 

be collected. 

Respondents: The data will be 

collected through private, selfadministered questionnaires completed 

by study participants, i.e. adolescents 

assigned to a select school or 

community teen pregnancy prevention 

program or a control group. Surveys will 

be distributed and collected by trained 

professional staff. Youth school records, 

performance, and program participation 

data will also be collected from 

participating schools and organizations, 

as appropriate to the site. 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES